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Abstract 
Approximately 10% of patients with Lyme disease will develop fatigue, 
musculoskeletal pain, difficulties of concentration or deficits in short-term memory within the 
6 months after treatment. This entity has been defined as Post Lyme Disease Syndrome or 
Post Treatment Lyme Disease Syndrome. The pathophysiology of this syndrome is not 
known, but neither persistence of the bacterium nor efficiency of antibiotics are currently 
sustained by the existing literature. In France, the Haut Conseil de Santé Publique has 
recently define a new entity called “persistent polymorphic semiology after tick bite” 
allowing to design studies to better understand these subjective manifestations, for which 
objective biomarkers currently lack. This entity encompasses patients suffering from fatigue 
and global pain in the months following a tick bite, and can be associated to several subjective 
symptoms with a major impact on quality of life.  
In interaction with the model of somatoform disorders, this article proposes a review of 
functional neuroimaging studies in patients with subjective complaints and discusses possible 
clinical implications for persisting symptoms after tick bites and Post Treatment Lyme 
Disease Syndrome. 
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Introduction 
In the absence of causal pathophysiological substrate and related biomarkers identifiable 
at individual level, complaints, symptoms and diseases are difficult to care, and consequently 
associated with medical nomadism, unnecessary costs for health systems and alteration of 
quality of life for patients [1]. In this line, objective biomarkers are helpful for the medical 
recognition of the subject as a patient, and subjective complaints as part of a disease to be 
supported by health policy. These biomarkers also contribute to better understand the associated 
pathophysiology which is an essential step of healthcare improvement through the 
determination of early diagnosis and prognosis, as well as the orientation and evaluation of 
therapeutics [2] 
Lyme disease is a complex infection with a number of well-known objective clinical 
manifestations. All of them respond well to conventional antibiotics [3]. However, 
approximately 10% of patients will develop fatigue, musculoskeletal pain, difficulties of 
concentration or deficits in short-term memory within the 6 months after treatment. This entity 
has been defined as Post Lyme Disease Syndrome (PLDS) or Post Treatment Lyme Disease 
Syndrome (PTLDS). The pathophysiology is not known, but neither persistence of the 
bacterium nor efficiency of antibiotics are currently sustained by the existing literature [4].  
Besides this syndrome, some medical doctors and patients’ associations advocate a 
“chronic Lyme disease”, which they believe to be due to chronic undetectable persistence of 
Borrelia. This entity is increasingly used in North America and Europe as a diagnosis for 
patients presenting with a myriad of subjective symptoms, such as pain, fatigue, neurocognitive 
deficits, and this with or without positive serology for Lyme disease. However, there is no 
current reproducible and convincing evidence of any relationship to Borrelia burgdorferi sensu 
lato infection. Consequently, the diagnosis is often based solely on the clinical judgement rather 
than on validated laboratory assays or even clinical criteria. In a recent work, H.M. Feder 
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identified four categories of patients in the “chronic Lyme” group [3]. The first was composed 
of patients with subjective symptoms, and no evidence of Borrelia infection. The second 
category of patients had a well-defined differential diagnosis (e.g. multiple sclerosis or 
autoimmune diseases) that could also explain the symptoms attributed to Lyme disease. Patients 
of the third category had a positive serology for Lyme disease, and symptoms of unknown cause 
but with no compatible history of symptoms compatible with Lyme disease. The last category 
corresponds to PTLDS. 
In France, the Haut Conseil de Santé Publique has recently define a new entity allowing 
to design studies to better understand these categories mainly composed of subjective 
manifestations, and for which we currently lack objective biomarkers [5]. This entity is called 
“persistent polymorphic semiology after tick bite” (PPSTB). It encompasses patients suffering 
from fatigue and global pain in the months following a tick bite, and can be associated to several 
subjective symptoms with a major impact on their quality of life.  
In interaction with the model of somatoform disorders, this article proposes a review of 
functional neuroimaging studies in patients with subjective complaints and discusses possible 
clinical implications for PPSTB/PTLDS. 
 
The model of “somatoform disorders” and “somatic symptoms & related disorders” 
In the fourth edition of the Diagnostic and Statistical Manual of Mental disorders (DSM-
IVTM), patients presenting with physical symptoms that were not fully explained by a medical 
condition, were considered as suffering from somatoform disorder [6]. However, the main 
characteristics of these patients is not physical symptoms per se, but instead the way they 
present and interpret them, as well as the significant distress and impairment they exhibit in 
response to their symptoms. The concept of somatoform disorder has therefore been criticized, 
because it overemphasized the lack of medical explanation. Furthermore, due to this absence of 
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medical explanation, individuals regarded this diagnosis as pejorative and demeaning, implying 
that their physical symptoms were not « real », or worst « hysterical ». This is the reason why, 
in the fifth edition of the Diagnostic and Statistical Manual of Mental disorders (DSM-5TM) [7] 
the category of “somatoform disorder” has been replaced by that of “somatic symptom and 
related disorder”, the common features of which is the presence of somatic symptoms plus 
abnormal thoughts, feelings, or behaviors in response to their symptoms. Interestingly, due to 
the presence of such abnormal thoughts, feelings or behaviors, the authors of DSM-5TM 
consider that somatic symptom disorders can also accompany diagnosed medical disorders.  
However, that does not mean that there should be a direct causal relationship between 
the latter and the former, or that they both pertain to the same disorder. The presence of a 
previous medical condition is just considered as a possible contributing factor to the 
development of a somatic symptom disorder [7]. This is particularly important to bear in mind, 
as individuals with somatic symptom disorders are commonly encountered in primary care and 
other medical settings, but are less commonly encountered in psychiatric and other mental 
health settings [7]. These patients may have multiple somatic symptoms, although sometimes 
only one severe symptom, most commonly pain, is present. Symptoms may be specific (e.g. 
localized anesthesia) or relatively unspecific (e.g. fatigue). These clinical characteristics are 
associated with persistent thoughts about the seriousness of symptoms, high level of anxiety 
about illness, excessive time and energy devoted to health concern, but sometimes only with a 
« belle indifference ».  
In the DSM-5TM, the chapter on “somatic symptom and related disorders” precisely 
includes the following disorders: somatic symptom disorder, illness anxiety disorder, 
conversion disorder (CD), psychological factors affecting other medical conditions, factitious 
disorder, other somatic symptom and related disorder and unspecified somatic symptom and 
related disorder. CD is probably the most popular and the most studied among these disorders. 
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Whereas it has been reported as a focus of treatment in 1-3% of outpatient referrals to mental 
health clinics, it shows a prevalence of 1-10% in medicine or surgery department, and up to 
30% in neurology department [8]. CD is considered as a functional central nervous system 
disorder, not caused by a neurological injury or a general medical condition [9] characterized 
by the presence of non-simulated neurological symptoms or deficits affecting voluntary motor 
or sensory functions, and often associated with dissociative symptoms, such as 
depersonalization, derealization and dissociative amnesia, particularly at symptom onset or 
during attacks. Importantly, not validating the disease as « organic » does not invalidate the « 
disease » as well [10]. Clinical findings usually show clear evidence of incompatibility with 
organic disease. Internal consistency at examination is one way to demonstrate incompatibility 
[7]. Nevertheless, the presence of a previous organic disease that causes similar symptoms is a 
classical risk factor, and the severity of the disability can be similar to that experienced by 
patients with comparable medical illnesses. Other risk factors comprise maladaptive personality 
traits, an history of childhood abuse and neglect, and the presence of stress or trauma, either 
psychological of physical in nature at disease onset [7].  
According to contemporary dissociation theory, conversion symptoms are generated 
preconsciously by an attentional gating mechanism: they are deemed to reflect a distortion in 
awareness resulting from information that has been « stuck » in the cognitive system. This 
inappropriate information has been called rogue representation or prior belief [11]. When the 
patient attempts to control cognition or action, the attempt is unsuccessful because the locus of 
patient’s deficit is the chronic activation and selection of rogue representation. According to 
this approach, conversion symptoms constitute an alteration in the body image generated by 
information in the cognitive system, rather than disturbances in the neural hardware itself. The 
fact that patients often have a history of physical illness suggests that many rogue 
representations arise out of memory traces acquired during episodes of organic pathology. The 
7 
 
physical components of emotional states also leave representations in memory that could 
provide the basis for the later development of conversion symptoms. Traumatic experiences 
such as physical or sexual abuse provide one of the richest sources of material for the 
development of rogue representations. One example may be the sensorimotor components of 
certain defensive reactions that occur in response to traumatic events. Other sources include 
indirect exposure to physical states in others, the sociocultural transmission of information 
about health and illness, and direct and verbal suggestion [11].  
 
Functional imaging as a biomarker of subjective complaints? 
Development of biomarkers are often driven by advances in medical imaging [2]. More 
specifically, functional imaging could assume a pivotal role in absence of detected lesion. For 
complaints or symptoms currently perceived as purely functional, as well as for early-stage 
diseases associated with only delayed lesions, functional imaging indeed provides more 
sensitive tools. Among them, functional MRI (fMRI) based on blood-oxygen-level dependent 
(BOLD) contrast is an increasingly available method for the research study of brain activity, at 
rest or during a paradigm of activation, among patients with neurological and psychiatric 
disorders, and in current clinical practice mostly for presurgical planning in patients presenting 
with a lesion close to a critically functional brain region [12]. On the other hand, PET and 
SPECT imaging contribute to identify molecular signature, usually at resting-state, through the 
targeting of biological processes by specific tracers radiomarked as radiopharmaceuticals [13]. 
The radioactive labelling provides optimal sensibility performance with sub-picomolar 
detection after the introduction of very small amount of tracer that not disrupts the molecular 
environment. In this line, amyloïdopathy is for example detectable with PET imaging at least 
15 years before cognitive deficits in Alzheimer’s disease [14], 50% of dopaminergic loss is 
identified with SPECT imaging at the early diagnosis of Parkinson’s disease [15], and a fronto-
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temporal dysfunction is identified in depression [16]. Among the various molecular targets, 
those related to cerebral blood flow (mainly with SPECT) and metabolic rate of glucose (PET 
with FDG, fluoro-deoxyglucose) are the most studied and validated at individual level. These 
two molecular processes are linked together, reflecting the brain energetic need to maintain 
synaptic activity through the neurovascular coupling [17], and have been widely used to explore 
functional and psychiatric diseases with a high sensitivity. In this line, international clinical 
recommendations exist for the evaluation of cognitive complaints associated with traumatic 
brain injury, as well as in psychiatric diseases for differential diagnosis and the follow-up of 
depression [18]. SPECT has for example shown perfusion abnormalities in TBI despite normal 
morphology, and results are considered to have a prognostic value for persistence of 
neuropsychological sequelae [19]. Besides these recommendations, research studies in 
functional imaging of patients with subjective complaints mostly concern somatoform disorders 
and CD, and also fibromyalgia and macrophagic myofasciitis.  
 
Functional neuroimaging abnormalities in somatic symptom disorders 
In patients with somatic symptom and conversion disorders, functional neuroimaging 
suggests brain changes distinct from feigning or healthy controls (for review [20]). These 
studies support the hypothesis of a specific alteration in emotion processing that triggers a large 
variety of symptoms through dysregulation of specific motor or sensory systems. 
 In details, selective reductions have been reported in the activity of frontal and 
subcortical circuits involved in motor control during hysterical paralysis, of somatosensory 
cortices during hysterical anaesthesia, and of visual cortex during hysterical blindness. 
Concomitantly, increased activation is found in limbic regions during conversion symptoms 
affecting different sensory or motor modalities. Taken together, these data generally do not 
support previous view that hysteria might involve an exclusion of sensorimotor representations 
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from awareness through attentional processes. They rather seem to point to a modulation of 
such representations by primary affective or stress-related factors, perhaps involving primitive 
reflexive mechanisms of protection and alertness that are partly independent of conscious 
control and mediated by dynamic modulatory interactions between limbic and sensorimotor 
networks. In this line, motor conversion symptoms have been characterized by the concomitant 
dysfunction of the following brain regions [9]: (i) salience network (amygdala, insula and 
cingulate cortices) that is connected with motor regions through supplementary motor area, (ii) 
prefrontal regions involved in behavioural control, (iii) ventromedial prefrontal cortex (vmPFC) 
regions that support self-monitoring and information processing about internal body states and 
environment, and (iv) self-agency network and regions involved in memory suppression. It was 
hypothesized that these dysfunctional brain networks may alter the selection of motor patterns 
through the influence of the supplementary motor area and the dorsolateral prefrontal cortex 
which are critical “hubs” connecting affective networks with regions underpinning motor 
control.  
This may result in deficient processing of either motor intention or disruption between 
motor intention and motor execution. Furthermore, an overactive self-monitoring with 
enhanced limbic neural activity, which interferes with movement planning, and initiation within 
frontal regions could contribute to disrupt motor execution [21]. The dysregulation of brain 
networks related to processing of emotions may also affect the integration of complex sensory 
inputs, and lead to functional sensory symptoms. Similar brain regions are involved in both 
positive and negative conversion symptoms, but differences concern the nature of the functional 
alterations (i.e. increased or decreased activity). Interestingly, hypnosis and conversion might 
share common neurophysiological mechanisms, with similar PET activations in hypnotic 
paralysis and conversion hysteria [22], with interactions between emotional regions and the 
motor/sensory systems.  
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Functional neuroimaging abnormalities in Fibromyalgia and Macrophagic Myofasciitis 
Fibromyalgia syndrome is a chronic pain condition characterised by widespread 
musculoskeletal aches, pain and stiffness, soft tissue tenderness, general fatigue and sleep 
disturbances, without a clinically demonstrable peripheral nociceptive cause [23]. Although a 
psychogenic cause was initially postulated, fMRI activation studies have demonstrated global 
dysfunction of central pain processing, consolidating the hypothesis of central sensitisation 
[24]. Similar painful pressure applied in patients and in controls did not result in activation of 
any common cerebral areas and showed greater effects in patients. On the other hand, similar 
brain patterns are obtained for a same intensity of provoked pain, obtained for lower stimuli in 
patients in comparison to healthy subjects. Interestingly, these functional abnormalities have 
been also reported at resting-state at individual-level in absence of provoked pain, in 
hyperalgesic patients with fibromyalgia using SPECT imaging [25]. These abnormalities could 
be related to metabolism of adenosine [26]. In details, hyperperfusions were found in primary 
somato-sensory cortices, in regions of the brain known to be involved in the sensory dimension 
of pain processing, while hypoperfusions were found in frontal, cingulate, medial temporal and 
cerebellar cortices, in areas assumed to be associated with the affective-attentional dimension 
of the pain. Interestingly, these abnormalities were correlated with the alteration of quality of 
life as subjectively evaluated by patients’ reports [27]. Moreover, asymmetrical symptoms were 
associated with asymmetrical functional abnormalities [28]. As current pharmacological and 
non-pharmacological therapies act differently on the different components of pain, functional 
neuroimaging could be a valuable and readily available tool to guide individual therapeutic 
strategy and provide objective follow-up of pain processing recovery under treatment [29]. In 
this line, relationship with predictive response and follow-up of the recovery have been 
described with ketamine, transcranial magnetic stimulation, and hyperbaric oxygen therapy 
[30–33].  
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On the other hand, macrophagic myofasciitis is a controversial condition associated with 
myopathological alterations. A peculiar FDG-PET pattern has been reported with  
hypometabolisms involving occipito-temporal cortex and cerebellum [34], and also described 
with perfusion SPECT [35]. These patterns have been reported to be associated with distinct 
cognitive profiles [35]. Interestingly, individual classification approach showed very high level 
of performance to distinguish between patients and healthy subjects, suggesting possible 
diagnostic value [36].  
 
Functional neuroimaging abnormalities in Lyme disease 
Few data have been reported concerning functional brain imaging in patients with 
subjective symptoms attributed to Lyme disease. Newberg et al. have studied 23 patients with 
a positive serology for Lyme disease (the serological method and titers were not described) 
suffering from cognitive disorder, visual disturbances and fatigue. They described FDG-PET 
temporal hypometabolism in 74% of patients at resting-state, possibly in line with memory 
deficits [37]. Seven of the patients with temporal lobe hypometabolism had diffuse cortical 
hypometabolism that included the frontal and parietal lobes. Donta et al. studied with brain 
SPECT, 183 patients defined as “chronic Lyme disease”, with negative and positive serologies 
and mainly subjective symptoms [38]. The authors identified abnormalities in 75% of them. 
Interestingly, antibiotherapy resulted in resolution or improvement of abnormalities in 70% of 
patients over a 1- to 2-year period. 
 
Clinical cases of the use of FDG-PET imaging in patients with subjective complaints 
In clinical practice, it is possible that FDG-PET will allow resolving a number of 
problems linked to psychogenic or organic origins. For example, it has recently been the case 
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in the consultation of one of us (DR), for suspicion of cerebral Whipple disease without 
identification of pathogen, because this infection can have cerebral manifestations without 
peripheric localization. 
A cerebral FDG-PET has been performed at resting-state in two patients. The first one 
was a 40-year old woman presenting a non-organic hemiplegia and the FDG-PET was typical 
of this pathology with a slight diminution of frontal and amygdala metabolism on the opposite 
side of the hemiplegia (Figure 1A). The visualization of this image allowing her to feel 
recognized as a patient, and not any more classified as an “unsick” or “simulating” person. 
The second patient was a 35-year-old woman, who had a peculiar emotive context that 
made difficult the assessment of her symptoms. She showed a generalized cerebral moderate 
hypometabolism (Figure 1B) as can be observed in cerebral Whipple disease [39]. As a 
therapeutic test, doxycycline and plaquenil treatment has been introduced and surprisingly, after 
six months of treatment, cerebral metabolism was entirely restored (Figure 1C), and was 
comparable to any other people of her age.  
In these two cases, cerebral FDG-PET allowed orientation of the diagnosis and in the 
second case, it allowed an empirical treatment that was efficient clinically and metabolically. 
 
Perspectives: therapeutic implications 
Current conceptions of somatoform disorders, reinforced by the findings of 
neuroimaging studies, have led to the use of novel therapeutic approaches. Two recent 
systematic reviews [21,40] have shown that non-invasive brain stimulation techniques, 
including electro-convulsive therapy (ECT) and mainly repetitive transcranial magnetic 
stimulation (rTMS) were liable to improve conversion symptoms, as also showed for rTMS 
with depression [16,41–49] or fibromyalgia [32] in line with neuroimaging biomarkers. In the 
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studies included in these reviews, it was found that the stimulation of the motor cortex 
contralateral to the corresponding paralysis was able to restore the motor function in 
somatoform disorders. In some cases [21,50], the associated sensory symptoms improved as 
well. In accordance with the results of neuroimaging studies, it was hypothesized that rTMS 
could enhance or substitute an insufficient input to the motor cortex from failing frontal 
executive areas, and thereby open the way to the learning process that lead to the reacquisition 
of limb use [51]. Furthermore, as rTMS induces noticeable involuntary contractions, these 
effects may allow the patients to become aware of the possibility of movement and thus of the 
integrity of the motor pathways [21]. This could contribute to correct patient’s rogue 
representation and lead to a change in prior belief [40]. 
The question as to whether complementary stimulations in other cortical regions than 
the primary cortex could enhance therapeutic efficacy of rTMS remains open. It has been 
proposed, in case of functional blindness, that the experience of phosphenes during visual 
cortex stimulation may act in an analogous manner to experiencing the movement of a “paretic” 
limb in re-establishing normal function [15]. In a more theoretical vein, brain stimulation 
techniques are likely to be used in order to correct the functional abnormalities in central 
networks that may be involved in the pathophysiology of somatoform disorders.    
Interestingly, recent findings are in line with the three assumptions that support the new 
classification framework project launched by National Institute of Mental health (NIMH) for 
research on mental disorders [52]. First, mental disorders are brain disorders but, in contrast to 
neurological disorders with identifiable lesions, they can be addressed as disorders of brain 
circuits. Second, the dysfunction in neural circuits can be identified with the tools of clinical 
neuroscience. Third, data from clinical neuroscience will yield biosignatures that will augment 
clinical symptoms for clinical management.  
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Many of the clinical manifestations exhibited by patients with persisting symptoms after 
tick bites and/or Post Treatment Lyme disease Syndrome are also encountered in those with 
somatic symptom and related disorders, including CD. Furthermore, either tick bites, Lyme 
Disease or the sociocultural transmission of information about them may favor, as previously 
shown, the development of somatic symptom disorders in individuals at risk. It may be therefore 
crucial to correctly identify patients with these disorders whose symptoms were previously 
considered as unexplained. In this regard patients’ attitudes, thoughts, feelings or behaviors 
may be of help. But even more, the specific patterns that modern brain imagery is able to 
evidence. The correct identification of these patients may allow to provide more specific 
therapeutic approaches, on the basis of functional neuroimaging. Consequently, there is an 
urgent need to conduct neuroimaging research in patients with persisting symptoms after tick 
bites and/or Post Treatment Lyme Disease. 
It is the psychiatrists’ hope that we may enter a time in which even “hysteria” patients 
could benefit from progress in Neurosciences. Aren’t infectiologists sharing the same hope for 
their “chronic Lyme” patients?            
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Figure 1 
 
 
 
FDG-PET slices of two recent patients explored at resting-state for subjective complaints. 1A 
(first patient): axial and coronal slices show left moderate hypometabolism of the amygdala 
(yellow arrow) and slight hypometabolism of the central region (white arrows). 1B (second 
patient): axial slices with diffuse cortical moderate hypometabolism, normalized in 1C after 
treatment by doxycycline and plaquenil. 
